EARLY Labs is a Bio-Tech company, operating in the field of Volatile Organic Compound based diagnostics.
The company is developing a revolutionary multi-cancer test platform, currently focusing on lung cancer, detecting lung cancer in urine samples, from it's earliest stages – with groundbreaking 90% stage I sensitivity and specificity results.
By Q4 2024 the platform will be calibrated to run Colon testing as well, and other cancer types to follow.
Simplicity of the test, which can be done at home or at pharmacies, using a urine collection kit, is expected to break existing uptake barriers such as invasiveness, radiation, long waiting lists, inconvenience and more, and completely change the cancer screening paradigm.